Abstract library

179 results for "ki67".
#1830 Increase of the Ki67 Proliferation Index over Time in Patients with Neuroendocrine Neoplasms
Introduction: Whether the Ki67 index increases over time in relation to progression is scarcely studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Pernille Holmager
#1148 Ki67 as a Prognostic Marker in Neuroendocrine Tumours: A Systematic Review of the Literature and Quantitative Synthesis of 5 year Survival Data
Introduction: The ENETS guidelines classify Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs) according to the histological assessment of tumour mitotic count or Ki67 labelling index (LI) on paraffin-embedded tissue, because proliferation rate has been shown to strongly correlate with prognosis. Since the guidelines were published, Ki67 has been established as the more reproducible measure, and further large case series have been reported.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Judith Cave
Keywords: GEP-NET, prognosis, Ki67
#1803 Type 3 Gastric Neuroendocrine Neoplasms: Relationship Between Tumor Size, Ki67 and Clinical Outcome
Introduction: Sporadic type 3 gNENs are usually malignant with high metastatic potential, mostly large, with a high grade histology. However, little is known on the relationship between tumor size, proliferative index Ki67, and clinical outcome
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Francesco Panzuto
#1852 Is Ki67 Index in Biopsy Tissue Truly Reflect Grading of Pancreatic Neuroendocrine Neoplasm?
Introduction: Ki67 index is essential for progression and treatment of pancreatic neuroendocrine neoplasm (pNEN). For advanced pNEN patient(pts), Ki67 scoring by core/fine-needle biopsy is used to evaluate pNEN pts’ grade.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Heli Gao
Authors: Gao H, Jin K, Wang W, Zhang S, ...
Keywords: pNEN, Ki67, biopsy, surgery
#1753 Ki67 Is Able to Predict Pancreatic NENs Prognosis Irrespective of Their Size
Introduction: In pancreatic neuroendocrine neoplasms (pNENs), size <20mm and Ki67≤2% suggest indolent behavior. None of these factors alone predicts prognosis. No other predictive factors have been suggested.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: MD, PhD Massimo Milione
Keywords: Ki67, PFS, pancreatic, NEN
#1116 Streptozotocin Based Chemotherapy in Advanced G2 Pancreatic Neuroendocrine Tumors (PNET): Efficacy According to KI67 Index
Introduction: Streptozotocin (STZ) with fluorouracil (FU) or doxorubicin (DOX) is approved in well differentiated advanced pancreatic neuroendocrine tumors (PNET).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: PhD Paula Jiménez-Fonseca
#1706 Effectiveness of Chemoterapy in Advanced PanNETs with ki67<55%: Monocentric Experience
Introduction: Pancreatic Neuroendocrine Tumors (panNETs) are neoplasms with heterogeneous clinical behaviour. There is no standard treatment.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Maria Antista
#1609 Prognostic Relevance of Pancreatic Neuroendocrine Tumors Grading on EUS-FNA
Introduction: Since WHO 2010, resected pNETs are graded as G1, G2 or G3 using the Ki67-LI. EUS-FNA is often used for diagnosis but few studies have assessed its value for grading.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Prof. Dr. Ivan Borbath
Keywords: EUS-FNA, KI67, pNET, OS
#1124 Correlation Between the 18F-FDG Uptake and Pathological Data in Well-Differentiated Digestive and Pulmonary Neuroendocrine Tumors (NET)
Introduction: The 18F-FDG uptake assessed by PET/CT is correlated to prognosis in most tumors.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Margot Bucau
#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience
Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego